News | Magnetic Resonance Imaging (MRI) | May 09, 2022

CVRx Receives MR-conditional Labeling Approval for its Barostim Heart Failure System

Heart failure patients implanted with Barostim can now receive conditional MRI scans

Heart failure patients implanted with Barostim can now receive conditional MRI scans

May 9, 2022 — CVRx, Inc., developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling for its Barostim System.

The Barostim System now includes instructions to allow for safe MRI scans of the head and lower extremities, meaning heart failure patients implanted with Barostim have more diagnostic options. All Barostim System patients, including those already receiving Barostim therapy, can safely receive an MRI at 1.5T when conditions of use are met.

"This is a significant milestone for CVRx, and more importantly, for the heart failure patients benefitting from our therapy," said Nadim Yared, President and CEO of CVRx. "These heart failure patients undergo many physical assessments. This approval expands the diagnostic imaging options available to physicians for these patients, should the need arise."

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body’s needs for blood and oxygen. Barostim works by stimulating baroreceptors – natural sensors in the body that tell the nervous system how to regulate heart, kidney and vascular function. These effects reduce the heart’s workload and help it pump more efficiently, helping to improve the symptoms for patients with heart failure. In the BeAT-HF Study, patients who had Barostim implanted were able to walk further in a 6-minute hall walk test, have a higher quality of life and appeared to have a reduction in the rate of serious cardiovascular events, including arrythmias, compared to the control group.

For more information: www.cvrx.com


Related Content

News | Magnetic Resonance Imaging (MRI)

February 21, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with ...

Home February 21, 2024
Home
News | Magnetic Resonance Imaging (MRI)

November 17, 2023 — Researchers from the University of Minnesota Medical School examining the cause of cardiomyopathy ...

Home November 17, 2023
Home
News | Magnetic Resonance Imaging (MRI)

June 28, 2023 — Liver disease, the UK’s third leading cause of premature death, poses a significantly greater threat to ...

Home June 28, 2023
Home
News | Magnetic Resonance Imaging (MRI)

June 20, 2023 — The US Food and Drug Administration has approved the use of iTFlow in blood flow analysis. The FDA ...

Home June 20, 2023
Home
News | Magnetic Resonance Imaging (MRI)

June 7, 2023 — GE HealthCare announced the FDA clearance and launch of Sonic DL – a state-of-the-art deep learning-based ...

Home June 07, 2023
Home
Feature | Magnetic Resonance Imaging (MRI) | By Johnson Polakkal Joseph

Magnetic resonance imaging (MRI) is a technology that has been around for more than four decades and is a staple in ...

Home May 01, 2023
Home
News | Magnetic Resonance Imaging (MRI)

April 18, 2023 — Findings from an award-winning Scientific Online Poster presented during the 2023 ARRS Annual Meeting ...

Home April 18, 2023
Home
News | Magnetic Resonance Imaging (MRI)

April 4, 2023 — Medtronic has announced the launch of MRI Care Pathway, a new system that can streamline the process of ...

Home April 04, 2023
Home
News | Magnetic Resonance Imaging (MRI)

November 17, 2022 — HeartVista, a pioneer in AI-assisted MRI solutions, and Siemens Healthineers, a global leader in ...

Home November 17, 2022
Home
News | Magnetic Resonance Imaging (MRI)

November 9, 2022 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), left ...

Home November 09, 2022
Home
Subscribe Now